scispace - formally typeset
S

Sarah E Jackson

Researcher at University College London

Publications -  190
Citations -  5096

Sarah E Jackson is an academic researcher from University College London. The author has contributed to research in topics: Population & Smoking cessation. The author has an hindex of 26, co-authored 167 publications receiving 2782 citations.

Papers
More filters
Journal ArticleDOI

Association of depression symptoms with receipt of healthcare provider advice on physical activity among US adults

TL;DR: In the US, fewer than one in three adults experiencing symptoms of depression report having received exercise advice from a healthcare provider, suggesting providing such advice may be a sustainable clinical strategy in reducing the incidence and severity of depression symptoms.
Journal ArticleDOI

Associations Among Physical Activity, Sedentary Behavior, and Weight Status With Sexuality Outcomes: Analyses from National Health and Nutrition Examination Survey.

TL;DR: Novel modifiable behavioral and biological antecedents of sexuality outcomes are identified among physical activity, sedentary behavior, and weight status with sexual activity and number of previous sexual partners in a representative sample of U.S. adults.
Journal ArticleDOI

Long-term evaluation of the rise in legal age-of-sale of cigarettes from 16 to 18 in England: a trend analysis

TL;DR: There is some evidence from an assessment of long-term trends in the Smoking Toolkit Study that the increase in legal age-of-sale of cigarettes in England was associated with a greater long- term decline in ever smoking among those aged 16–17 compared with those aged 18–24.
Journal ArticleDOI

Ethnic Differences in Magnesium Intake in U.S. Older Adults: Findings from NHANES 2005–2016

TL;DR: The results highlight the need for targeted interventions to increase magnesium intake in U.S. older adults, with a focus on African Americans, in order to reduce the burden of morbidity and ethnic inequalities in health in later life.
Journal ArticleDOI

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors.

TL;DR: In this article, the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) trial using Bayes factors provides moderate to strong evidence that use of varenicline, bupropion or nicotine patches for smoking cessation does not increase the risk of neuropsychiatric adverse events relative to use of placebo in smokers without a history of psychiatric disorder.